Latest Conference Coverage

Jaydev Thakkar, chief operating officer, Biofourmis discusses how Biofourmis got involved with the CancerX Initiative at the 2023 DIA annual meeting in Boston, MA.

Jaydev Thakkar, chief operating officer, Biofourmis discusses the work his organization is doing within the CancerX initiative at the 2023 DIA annual meeting in Boston, MA.

Jaydev Thakkar, chief operating officer, Biofourmis gives an overview of the CancerX initiative at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders gives an overview of the EFGCP eConsent Initiative at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders gives an overview of eConsent at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders discusses takeaways from a 2023 DIA session she spoke at on eConsent.

Follow Group Social Media Editor, Miranda Schmalfuhs, as she and the rest of the team attend the DIA 2023 conference in Boston, MA.

Emily Botto, research analyst, Tufts CSDD speaks about a recent study on the impact of exclusionary behaviors on team dynamics conducted by Tufts at the 2023 DIA annual meeting in Boston, MA.

Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb speaks about returning patient data at the 2023 DIA annual meeting in Boston, MA.

Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb speaks about giving patients more power in decision making at the 2023 DIA annual meeting in Boston, MA.

Panel explores challenges that could affect their development.

DIA 2023 session focuses on taking patient feedback, how to implement them into trials, and measuring the impact they have on processes.

DIA session focuses on the ins and outs of returning individual participant data.

Session offers a look into the Inflation Reduction Act’s impact on market conditions.

Session explores practicality of models for selling low-cost drugs.

DIA session highlights strategies for stakeholders to make clinical trials more inclusive for diverse populations.

Panel at DIA discussed the evolving role of pharmacies in clinical trials.

Sponsors offers patient and caregiver insights on hybrid and decentralized clinical trial design provided by their feedback processes.

Speakers dive into the importance of risk-based methods and central-monitoring solutions as they pertain to these trials.

What does the future of digital health look like?